Brief: Prothena To Present Data On Survival Benefit Observed In Completed Phase 3 Study Of Drug Candidate Birtamimab In Patients With Mayo Stage Iv Al Amyloidosis At The Ash 2022 Meeting
03/11/2022 15:02
Nov 3 (Reuters) - Prothena Corporation PLC PRTA.O :
* PROTHENA TO PRESENT DATA ON SURVIVAL BENEFIT OBSERVED IN
COMPLETED PHASE 3 STUDY OF DRUG CANDIDATE BIRTAMIMAB IN PATIENTS
WITH MAYO STAGE IV AL AMYLOIDOSIS AT THE ASH 2022 MEETING
Source text for Eikon: ID:nBw86HnXCa
Further company coverage: PRTA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Prothena
See all newsProthena Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Prothena's Q2 net loss narrows on lower expenses
Brief: Prothena Q2 Net Income USD -18.583 Million
Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview
Prothena posts Q1 revenue surge fueled by $50 million Novo Nordisk milestone payment